A Multicenter, Randomized, Double-Blind, Parallel-Group Fixed-Dose Study of the Effect on Weight of Befeprunox Versus Olanzapine in the Treatment of Outpatients With Schizophrenia.

NCT00380224 Phase 3 COMPLETED

This study will compare bifeprunox to a currently marketed medication, Zyprexa (olanzapine), with respect to the affect on weight during the treatment of outpatients with schizophrenia. The study will compare the effect of these medications on several variables, including body weight and triglyceride levels.

Details

Lead sponsor	Wyeth is now a wholly owned subsidiary of Pfizer
Phase	Phase 3
Status	COMPLETED
Enrolment	120
Start date	2006-07
Completion	2007-09

Conditions

• Schizophrenia

Interventions

• bifeprunox, olanzapine

Primary outcomes

• Change from baseline on body weight at the final evaluation.

Countries

United States